摘要 |
The present invention provides combination therapy methods, formulations and kits useful for managing or treating a CA 125-related disorder or symptom thereof. In one aspect, the present invention provides methods for managing or treating a cell proliferative disorder, such as a cancer, for example, ovarian cancer, comprising administering a combination of (a) a sensitizer, such as, for example, paclitaxel, and (b) an antibody that preferentially binds cell-associated CA 125 polypeptides relative to shed CA 125 polypeptides, hi some embodiments of the methods provided, the antibody is conjugated to a cytotoxic agent such as a radiolabel. In another aspect, the present invention provides pharmaceutical compositions comprising (a) a sensitizer; (b) an antibody that preferentially binds cell-associated CA 125 polypeptides relative to shed CA 125 polypeptides; and, (c) a pharmaceutically acceptable excipient, diluent, or carrier. |